These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19414323)

  • 41. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
    Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
    Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
    Shin JY; Yoon IH; Kim JS; Kim B; Park CG
    Cell Immunol; 2009; 256(1-2):72-8. PubMed ID: 19249018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of vascular endothelial growth factor (VEGF) in neoplastic and tuberculosis effusions--preliminary results].
    Jankowska R; Porebska I; Dyła T
    Pneumonol Alergol Pol; 2002; 70(5-6):258-64. PubMed ID: 12518624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Anti-CCR4 mAb and regulatory T cells].
    Kurose K; Ohue Y; Oka M
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
    DeLong P; Carroll RG; Henry AC; Tanaka T; Ahmad S; Leibowitz MS; Sterman DH; June CH; Albelda SM; Vonderheide RH
    Cancer Biol Ther; 2005 Mar; 4(3):342-6. PubMed ID: 15846066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer.
    Landt S; Heidecke H; Korlach S; Reuter C; Schwidde I; Barinoff J; Thill M; Sehouli J; Kümmel S
    Anticancer Res; 2011 Aug; 31(8):2609-15. PubMed ID: 21778312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism.
    Ye ZJ; Zhou Q; Zhang JC; Li X; Wu C; Qin SM; Xin JB; Shi HZ
    Respir Res; 2011 Jun; 12(1):77. PubMed ID: 21663645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
    Thomas AA; Fisher JL; Hampton TH; Christensen BC; Tsongalis GJ; Rahme GJ; Whipple CA; Steel SE; Davis MC; Gaur AB; Lewis LD; Ernstoff MS; Fadul CE
    Cancer Immunol Immunother; 2017 Mar; 66(3):379-389. PubMed ID: 27942839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor Infiltrating Effector Regulatory T Cells Express VEGF Receptor 2 in Patients With Colorectal Cancer.
    Tsumuraya H; Mimura K; Nakajima S; Hanayama H; Matsuishi A; Okayama H; Fukai S; Ito M; Ashizawa M; Chida S; Onozawa H; Sakamoto W; Saito M; Saze Z; Momma T; Kono K
    Anticancer Res; 2024 Jul; 44(7):2933-2941. PubMed ID: 38925828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelets take up the monoclonal antibody bevacizumab.
    Verheul HM; Lolkema MP; Qian DZ; Hilkes YH; Liapi E; Akkerman JW; Pili R; Voest EE
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5341-7. PubMed ID: 17855648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Changes and the implications of CD4(+);CD25(+);CD127(low); regulatory T cells in drug addicts during natural drug withdrawal].
    Wang W; Zhang R; Xing Y; Zhang S; Hu D; Wu J; He J; Yang X; Fu J; Zhao H; Hu L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Oct; 29(10):1072-5. PubMed ID: 24103268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
    Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
    Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating biomarkers of bevacizumab activity in patients with breast cancer.
    Denduluri N; Yang SX; Berman AW; Nguyen D; Liewehr DJ; Steinberg SM; Swain SM
    Cancer Biol Ther; 2008 Jan; 7(1):15-20. PubMed ID: 18059178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.
    Hoyer RJ; Leung N; Witzig TE; Lacy MQ
    Am J Hematol; 2007 May; 82(5):409-13. PubMed ID: 17326106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.
    Bradshaw M; Mansfield A; Peikert T
    Curr Oncol Rep; 2013 Jun; 15(3):207-16. PubMed ID: 23568600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
    Varey AH; Rennel ES; Qiu Y; Bevan HS; Perrin RM; Raffy S; Dixon AR; Paraskeva C; Zaccheo O; Hassan AB; Harper SJ; Bates DO
    Br J Cancer; 2008 Apr; 98(8):1366-79. PubMed ID: 18349829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
    Gao F; Yang C
    Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
    Johnson BF; Clay TM; Hobeika AC; Lyerly HK; Morse MA
    Expert Opin Biol Ther; 2007 Apr; 7(4):449-60. PubMed ID: 17373897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.